BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 22, Issue 46
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study
©The Author(s) 2016.
World J Gastroenterol. Dec 14, 2016; 22(46): 10210-10218
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10210
Table 2 Patient demographics after 48 wk of therapy
PegIFNα-2aETVP value
HBsAg levels (log10 IU/mL)3.13403.69500.001
HBsAg loss rate (%)15.910.00000.0182
α = 0.05.
1Non-parametric Wilcoxon test;
2Pearson’s χ2 test. HBsAg: Hepatitis B surface antigen; PegIFNα-2a: PEGylated interferon-α-2a; ETV: Entecavir.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.